CU20150179A7 - Letermovir amorfo y formulaciones farmacéuticas sólidas del mismo para administración por via oral - Google Patents
Letermovir amorfo y formulaciones farmacéuticas sólidas del mismo para administración por via oralInfo
- Publication number
- CU20150179A7 CU20150179A7 CUP2015000179A CU20150179A CU20150179A7 CU 20150179 A7 CU20150179 A7 CU 20150179A7 CU P2015000179 A CUP2015000179 A CU P2015000179A CU 20150179 A CU20150179 A CU 20150179A CU 20150179 A7 CU20150179 A7 CU 20150179A7
- Authority
- CU
- Cuba
- Prior art keywords
- letermovir
- amorphous letermovir
- solid pharmaceutical
- pharmaceutical formulations
- amorfo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona letermovir amorfo y formulaciones farmacéuticas sólidas administrables por vía oral del mismo (formulación de liberación inmediata). Dicho letermovir amorfo es adecuado para formulaciones de liberación inmediata cuando se aísla de una disolución orgánica por cualquiera de secado con rodillos de dicha disolución orgánica en un disolvente orgánico volátil, en particular acetona, a una temperatura de 30°C a 60°C, y posteriormente secado del letermovir amorfo obtenido, o aislamiento de dicho letermovir amorfo mediante precipitación en disolventes miscibles con agua seleccionados de acetona o acetonitrilo en exceso de agua como antidisolvente, y posteriormente filtración o centrifugación del letermovir amorfo obtenido. Las formulaciones de liberación inmediata de letermovir amorfo están previstas para su uso en métodos de profilaxis o métodos de tratamiento de enfermedades asociadas al grupo de Herpes viridae, preferentemente asociadas a citomegalovirus (CMV), incluso más preferentemente asociadas a citomegalovirus humano (CMVH).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13003120 | 2013-06-19 | ||
EP14165027 | 2014-04-16 | ||
PCT/EP2014/062974 WO2014202737A1 (en) | 2013-06-19 | 2014-06-19 | Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20150179A7 true CU20150179A7 (es) | 2016-07-29 |
CU24619B1 CU24619B1 (es) | 2022-08-09 |
Family
ID=50982905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2015000179A CU24619B1 (es) | 2013-06-19 | 2014-06-19 | Letermovir amorfo y formulaciones farmacéuticas sólidas del mismo para administración por via oral |
Country Status (34)
Country | Link |
---|---|
US (1) | US10442773B2 (es) |
EP (1) | EP3010891B1 (es) |
JP (2) | JP6445546B2 (es) |
KR (1) | KR101953270B1 (es) |
CN (1) | CN105555771A (es) |
AU (1) | AU2014283231B2 (es) |
BR (1) | BR112015031979B1 (es) |
CA (1) | CA2916143C (es) |
CU (1) | CU24619B1 (es) |
CY (1) | CY1121732T1 (es) |
DK (1) | DK3010891T3 (es) |
DO (1) | DOP2015000303A (es) |
EA (1) | EA036131B1 (es) |
ES (1) | ES2730958T3 (es) |
HK (1) | HK1223935A1 (es) |
HR (1) | HRP20190936T1 (es) |
HU (1) | HUE043721T2 (es) |
IL (2) | IL243228B (es) |
LT (1) | LT3010891T (es) |
MD (1) | MD4673C1 (es) |
ME (1) | ME03483B (es) |
MX (1) | MX2015017758A (es) |
MY (1) | MY179502A (es) |
NZ (1) | NZ715387A (es) |
PE (1) | PE20160659A1 (es) |
PH (1) | PH12015502821B1 (es) |
PL (1) | PL3010891T3 (es) |
PT (1) | PT3010891T (es) |
RS (1) | RS58882B1 (es) |
SG (1) | SG11201510426PA (es) |
SI (1) | SI3010891T1 (es) |
UA (1) | UA117755C2 (es) |
WO (1) | WO2014202737A1 (es) |
ZA (1) | ZA201509239B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10319612A1 (de) | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
DE102012101673A1 (de) | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
JP6445546B2 (ja) * | 2013-06-19 | 2018-12-26 | アイキュリス アンチ−インフェクティブ キュアズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 非晶質レテルモビル及び経口投与のためのその固形医薬製剤 |
AU2017244984A1 (en) | 2016-03-31 | 2018-11-01 | Intercept Pharmaceuticals, Inc. | Oral preparation having exceptional elutability |
EP3938353A4 (en) * | 2019-03-12 | 2022-12-28 | Microbiotix, Inc. | COMBINATION DRUG TREATMENT FOR HUMAN CYTOMEGALOVIRUS |
CN111024861A (zh) * | 2019-12-31 | 2020-04-17 | 山东省药学科学院 | 一种莱特莫韦及含莱特莫韦的制剂中有关物质的检测方法 |
EP3906929A1 (en) | 2020-05-08 | 2021-11-10 | AiCuris GmbH & Co. KG | Letermovir for use in the prevention and the treatment of coronavirus infections |
WO2022038457A1 (en) * | 2020-08-17 | 2022-02-24 | Lupin Limited | A precipitation process for amorphous letermovir |
EP4262805A1 (en) * | 2020-12-16 | 2023-10-25 | Merck Sharp & Dohme LLC | Mini-tablet dosage form of a viral terminase inhibitor and uses thereof |
CN115403528A (zh) * | 2021-05-27 | 2022-11-29 | 南京正大天晴制药有限公司 | 无定形3,4-二氢喹唑啉衍生物的制备方法 |
CN114942278B (zh) * | 2022-04-12 | 2023-09-08 | 山东诚创蓝海医药科技有限公司 | 来特莫韦中间体二d-(+)-二对甲基苯甲酰酒石酸乙酸乙酯络合物有关物质的分析方法 |
WO2024037485A1 (zh) * | 2022-08-15 | 2024-02-22 | 上海迪赛诺化学制药有限公司 | 一种来特莫韦无定形的制备方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10207026A1 (de) * | 2002-02-20 | 2003-08-28 | Boehringer Ingelheim Kg | Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung |
DE10319612A1 (de) * | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
DE10305785A1 (de) * | 2003-02-12 | 2004-08-26 | Bayer Healthcare Ag | Dihydrochinazoline |
DE10338402A1 (de) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum |
EP1871345B1 (en) * | 2005-04-12 | 2012-08-01 | Elan Pharma International Limited | Nanoparticulate erlotinib formulations |
DE102005027517A1 (de) * | 2005-06-15 | 2006-12-21 | Bayer Healthcare Ag | Verfahren zur Herstellung von Dihydrochinazolinen |
EP2704570A4 (en) * | 2011-05-04 | 2015-02-18 | Merck Sharp & Dohme | ACTIVE SUBSTANCES, PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF |
DE102012101680A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat |
DE102012101659A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
DE102012101673A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
WO2014047562A2 (en) * | 2012-09-21 | 2014-03-27 | Epiphany Biosciences | Method of treating and/or preventing shingles and method of treating and/or preventing zoster associated pain |
JP6445546B2 (ja) * | 2013-06-19 | 2018-12-26 | アイキュリス アンチ−インフェクティブ キュアズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 非晶質レテルモビル及び経口投与のためのその固形医薬製剤 |
-
2014
- 2014-06-19 JP JP2016520499A patent/JP6445546B2/ja active Active
- 2014-06-19 RS RS20190686A patent/RS58882B1/sr unknown
- 2014-06-19 US US14/899,178 patent/US10442773B2/en active Active
- 2014-06-19 CN CN201480040969.XA patent/CN105555771A/zh active Pending
- 2014-06-19 ES ES14732545T patent/ES2730958T3/es active Active
- 2014-06-19 EA EA201600024A patent/EA036131B1/ru unknown
- 2014-06-19 MD MDA20150126A patent/MD4673C1/ro active IP Right Grant
- 2014-06-19 HU HUE14732545A patent/HUE043721T2/hu unknown
- 2014-06-19 DK DK14732545.0T patent/DK3010891T3/da active
- 2014-06-19 SI SI201431243T patent/SI3010891T1/sl unknown
- 2014-06-19 AU AU2014283231A patent/AU2014283231B2/en active Active
- 2014-06-19 UA UAA201600339A patent/UA117755C2/uk unknown
- 2014-06-19 NZ NZ715387A patent/NZ715387A/en unknown
- 2014-06-19 PT PT14732545T patent/PT3010891T/pt unknown
- 2014-06-19 CU CU2015000179A patent/CU24619B1/es unknown
- 2014-06-19 SG SG11201510426PA patent/SG11201510426PA/en unknown
- 2014-06-19 PL PL14732545T patent/PL3010891T3/pl unknown
- 2014-06-19 LT LTEP14732545.0T patent/LT3010891T/lt unknown
- 2014-06-19 KR KR1020167001010A patent/KR101953270B1/ko active IP Right Grant
- 2014-06-19 PE PE2015002639A patent/PE20160659A1/es unknown
- 2014-06-19 ME MEP-2019-149A patent/ME03483B/me unknown
- 2014-06-19 CA CA2916143A patent/CA2916143C/en active Active
- 2014-06-19 EP EP14732545.0A patent/EP3010891B1/en active Active
- 2014-06-19 MX MX2015017758A patent/MX2015017758A/es active IP Right Grant
- 2014-06-19 BR BR112015031979-3A patent/BR112015031979B1/pt active IP Right Grant
- 2014-06-19 MY MYPI2015002983A patent/MY179502A/en unknown
- 2014-06-19 WO PCT/EP2014/062974 patent/WO2014202737A1/en active Application Filing
-
2015
- 2015-12-18 ZA ZA2015/09239A patent/ZA201509239B/en unknown
- 2015-12-18 PH PH12015502821A patent/PH12015502821B1/en unknown
- 2015-12-18 DO DO2015000303A patent/DOP2015000303A/es unknown
- 2015-12-20 IL IL243228A patent/IL243228B/en active IP Right Grant
-
2016
- 2016-10-25 HK HK16112264.6A patent/HK1223935A1/zh unknown
-
2018
- 2018-09-07 JP JP2018168220A patent/JP6770035B2/ja active Active
- 2018-12-26 IL IL263978A patent/IL263978B/en active IP Right Grant
-
2019
- 2019-05-21 HR HRP20190936TT patent/HRP20190936T1/hr unknown
- 2019-06-11 CY CY20191100607T patent/CY1121732T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20150179A7 (es) | Letermovir amorfo y formulaciones farmacéuticas sólidas del mismo para administración por via oral | |
CO2020015437A2 (es) | Derivados de tetrahidro-imidazo[4,5-c]piridina como inmunomoduladores pd-l1 | |
CL2019001744A1 (es) | Derivados de benzoxazol como inmunomoduladores. | |
CO2018004589A2 (es) | Sales de valbenazina y polimorfos de las mismas | |
ECSP19003773A (es) | Compuestos heterocíclicos como inmunomoduladores | |
NI201900039A (es) | Derivados de 6, 7, 8, 9-tetrahidro-3h-pirazolo[4, 3-f] isoquinolina útiles en el tratamiento del cáncer | |
CU20170162A7 (es) | Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen | |
UY36112A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
UY33600A (es) | Análogos de carba-nucleósidos 2` - flúor sustituidos para tratamiento antiviral y uso de los mismos en la preparación de medicamentos | |
BR112015020819A2 (pt) | uso de faecalibacterium prausnitzii htf-f (dsm 26943) para supressão de inflamação | |
CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
CR20180493A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
UY37742A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
BR112018004617A2 (pt) | acetamida tienotriazoldiazepinas e usos das mesmas | |
CL2016000063A1 (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
MA43583A (fr) | Dérivés d'acide pentanoïque substitués par pyrrolo-[2,3-b]pyrimidne-pyridines pour traiter des infections par le virus de la grippe | |
CL2017000223A1 (es) | [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
CR20160529A (es) | Composiciones farmacéuticas para tratar enfermedades infecciosas | |
AR095032A1 (es) | Formulaciones de compuestos orgánicos, composición farmacéutica sólida comprimida por rodillo | |
WO2015031198A3 (en) | Bendamustine pharmaceutical compositions | |
EA202091493A1 (ru) | Аморфный летермовир и содержащие его твердые фармацевтические препараты, предназначенные для перорального введения | |
UY35600A (es) | "composiciones farmacéuticas que comprenden compuestos derivados de triazolopiridina y métodos para prepararlas" | |
BR112018012616A2 (pt) | formulação galênica que compreende um fármaco tópico | |
AR105503A1 (es) | Concentrado que contiene alprostadil | |
CO6670553A2 (es) | Derivados de 3 aminolactama aril sustituidas y composiciones farmaceúticas que lo comprenden |